Solvay Creon May Soon Find Competitors At The Trough
Executive Summary
Following a successful advisory committee, Solvay's Creon appears likely to become the only pancreatic enzyme product on the market with an approved NDA - at least for a little while
You may also be interested in...
Solvay Analyzing “Various Options” For Its Pharma Unit
Belgian firm, which co-markets TriLipix and TriCor with Abbott, confirms it is in discussions with third-parties.
Solvay Pancreatic Enzyme Creon May Set Class Labeling With Infection Warning
Solvay's post-marketing requirements will likely include ongoing surveillance of viruses in patients taking porcine-derived Creon and in the swine that produce it
Solvay Pancreatic Enzyme Creon May Set Class Labeling With Infection Warning
Solvay's post-marketing requirements will likely include ongoing surveillance of viruses in patients taking porcine-derived Creon and in the swine that produce it